China to allow some drugs based on foreign approvals

Image
AP Beijing
Last Updated : Oct 09 2017 | 9:32 PM IST
China will allow use of some drugs and medical devices based on approval by foreign regulators, the government said today, in a move that could help to ease access to its health care market.
The step was one of a series announced by Chinese drug regulators to improve access to treatments and streamline an approval process that foreign suppliers complain is too slow and complex.
The communist government is in the midst of a marathon effort to expand access to health care for China's 1.4 billion people. At the same time, it faces pressure from trading partners to open its markets for medical technology.
Regulators want to improve access to "urgently needed drugs and medical devices," the CFDA said in a statement.
"Regarding drugs and medical devices that already are approved to go on the market abroad, they will be allowed on the market with conditions attached," the agency said.
The agency gave no details of what products might be affected or how the approval process would work.
Suppliers of drugs and devices such as X-ray machines have long looked at China as a promising market but complain that a cumbersome approval process that can take up to seven years hampers market access.
In 2015, the CFDA promised to simplify drug approvals and clear a backlog of applications.
Despite such steps, suppliers say Beijing is backtracking in some areas, such as by excluding foreign products from catalogs used by hospitals to purchase medical equipment.
Also today, the CFDA said it would streamline the process for approving generic drugs, a step that could undercut potential demand for foreign products.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 09 2017 | 9:32 PM IST

Next Story